O
AXSM icon

OrbiMed’s Axsome Therapeutics AXSM Stock Holding History

OrbiMed’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50,000
Closed -$2.83M – 162
2021
Q1 		$2.83M Buy
+50,000
New +$3.52M 0.03% 149

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

OrbiMed's AXSM Position: Q2 2026 in Review

OrbiMed reduced its Axsome Therapeutics (AXSM) stake by 45% in Q2 2026, selling an estimated $20.9M and leaving 117,578 shares worth $28.8M. The position accounts for 0.53% of the portfolio, ranked #51.

OrbiMed first reported a position in AXSM in Q1 2025 and has held it in 6 quarters since. The position peaked at $64.6M in Q3 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • OrbiMed held 117,578 shares of Axsome Therapeutics worth $28.8M as of Q2 2026.
  • OrbiMed sold 96,343 Axsome Therapeutics shares in Q2 2026, an estimated $20.9M.
  • Axsome Therapeutics made up 0.53% of OrbiMed's portfolio in Q2 2026, its #51 holding.
  • OrbiMed first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • OrbiMed's Axsome Therapeutics position peaked at $64.6M in Q3 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.